Showing 2451-2460 of 3318 results for "".
- Halozyme Appoints Jean-Pierre Bizzari, MD to Board Of Directorshttps://practicaldermatology.com/news/halozyme-appoints-jean-pierre-bizzari-md-to-board-of-directors/2459021/Halozyme Therapeutics, Inc. appointed of Jean-Pierre Bizzari, MD to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development. "I am delighted to welcome Jean-Pierre to our Board of Directors," said Dr. Helen Torley, President and Chief Executi
- Cosmetic Surgery Forum Names 2014 Award Winnershttps://practicaldermatology.com/news/cosmetic-surgery-forum-names-award-winners/2459049/Cosmetic Surgery Forum, taking place later this week at the Palazzo Resort and Casino in Las Vegas, will recognize Dr. Carl Thornfeldt and Dr. Haines Ely for their respective career achievements and contributions to the field of cosmetic dermatology. Receiving the Innovators in Dermatolog
- Advanced Dermatology and Cosmetic Surgery (ADCS Clinics) Announces the Acquisition of Fort Collins Skin Clinichttps://practicaldermatology.com/news/20140903-advanced_dermatology_and_cosmetic_surgery_adcs_clinics_announces_the_acquisition_of_fort_collins_skin_clinic/2459132/ADCS Clinics (“ADCS”) announced it has completed the acquisition of Fort Collins Skin Clinic in Fort Collins, Colorado; a dermatology practice owned by Dr. Brad Baack and Dr. Andy Kalajian (both Board Certified Dermatologist and fellowship trained Mohs Micrographic Surgeons). Baack and Kalajian, wit
- Advanced Dermatology & Cosmetic Surgery, (ADCS Clinics) Acquires Lakeland Dermatology, Inc.https://practicaldermatology.com/news/20130906-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_lakeland_dermatology_inc/2459467/ADCS Clinics (“ADCS”) has completed the acquisition of Dr. David W. Murray's, dermatology practice located in Lakeland, Florida. Dr. Murray is Board-Certified - trained at the University of Oregon Health Sciences Center and did his residency at the Naval Hospital in San Diego. He spent 11 years in a
- Free Podcasts on Complete UV Protectionhttps://practicaldermatology.com/news/20120612-free_podcasts_on_complete_uv_protection/2459785/On the new edition of "Healthy Vision with Dr. Val Jones," dermatologist and author Jeanine Downie, MD, and Stephen Cohen, OD, past president of the Arizona Optometric Association, join Dr. Val to talk about the importance of sun protection. Both doctors share tips on steps adults and children can t
- Advanced Dermatology & Cosmetic Surgery (ADCS Clinics) Acquires The Grekin Skin Institutehttps://practicaldermatology.com/news/20140714-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_the_grekin_skin_institute/2459172/ADCS Clinics ("ADCS") announced it has completed the acquisition of The Grekin Skin Institute in Southfield, Michigan, a dermatology practice founded by Dr. Steven Grekin.
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo
- Analysis: New Biologics Account for 70% of Increased Medicare Dermatology Drug Spendinghttps://practicaldermatology.com/news/analysis-new-biologics-account-for-70-of-increased-medicare-dermatology-drug-spending/2475722/Spending on dermatology-related drugs under Medicare Part D nearly quadrupled between 2013 and 2022, with specialty medications (including biologics) responsible for the vast majority of that increase, according to a new study.
- Analysis: Drug Class Influences Clinical Management of Eruptive Keratoacanthoma/Squamous Cell Carcinomahttps://practicaldermatology.com/news/drug-class-influences-clinical-profile-and-management-of-eruptive-kascc/2474440/The clinical features and management of drug-induced eruptive keratoacanthoma (KA) and squamous cell carcinoma (SCC) differ significantly depending on the causative drug class, according to a new analysis of 172 reported cases.
- 2-Year Data: Bimekizumab Can Eliminate Draining Tunnels in HShttps://practicaldermatology.com/news/2-Year-Data-Bimekizumab-Can-Eliminate-Draining-Tunnels-HS/2471535/Two-year data from the BE HEARD trials for bimekizumab-bkzx (BIMZELX®) in moderate-to-severe hidradenitis suppurativa (HS) continued to demonstrate sustained disease control and durable relief from key HS symptoms, including the potential to help prevent long-term structural damage caused by drai